Exact Sciences' revenue jumps by 158% in Q3 — 5 insights

Exact Sciences reported net sales of $72.6 million in its third quarter fiscal year 2017 results.

Here's what you should know:

1. Exact Sciences increased sales 158 percent, year-over-year.

2. Exact Sciences completed 161,000 Cologuard tests in the third quarter. Test volume grew 136 percent, year-over-year.

3. Cologuard earned approximately $451 per test.

4. Exact Sciences CEO Kevin Conroy said in a release, "A growing number of patients and physicians are demanding Cologuard. Through our direct-to-consumer television and marketing campaign and our national sales force, we are reaching a larger percentage of the 80 million people eligible to be screened with Cologuard."

5. Concerning rest-of-year outlooks, Exact Sciences expects revenues between $254 million and $257 million for 2017. Exact Sciences estimates up to 177,000 more tests will be completed in the fourth quarter of 2017.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast